

Related Party Disclosures**i. Parties where control exists:**

- a) Sanofi S.A. France, ultimate holding Company
- b) Hoechst GmbH, Germany, holding Company

ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the reporting year.

Sanofi-Aventis Singapore Pte. Limited
Francopia S.A.R.L.
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Groupe S.A.
Sanofi Lanka Limited
Sanofi Chimie S.A.
Sanofi-aventis Philippines Inc.
Sanofi Pasteur India Private Limited #
Sanofi-Synthelabo (India) Private Limited #
Sanofi Healthcare India Private Limited
Sanofi Winthrop Industrie S.A.
Sanofi-Aventis Pakistan Limited *
Sanofi Aventis Arabia Co. Ltd. *
Sanofi India Limited Provident Fund
Sanofi US Services Inc.
Aventis Pharma UK Investments Ltd.
Sanofi Vietnam Shareholding Company
SANOFI-AVENTIS GESTION SA
Sanofi-aventis Healthcare Pty Ltd
* No transactions during the year
In the current year merged with Sanofi Healthcare India Private Limited

iii. Key management personnel of the Company for the year

Mr. Rajaram Narayanan - Managing Director
Mr. Cherian Mathew - Whole Time Director
Mr. Vaibhav Karandikar - Chief Financial officer (w.e.f October 06, 2020) and Whole time director (w.e.f February 23, 2021)
Mr. Charles Billard - Whole Time Director and CFO (till the closure of business of September 30, 2020)
Mr. Girish Tekchandani - Company Secretary (till the closure of business hours of August 31, 2021)
Ms. Radhika Shah - Company Secretary (w.e.f November 01, 2021)

iv. Non-Executive Directors

Mr. Cyril Grandchamp-Desraux (till the closure of business of November 24, 2021)
Mr. Thomas Rouckout (till the closure of business of February 25, 2020)
Dr. Shailesh Ayyangar (till the closure of business of February 25, 2020)
Mr. Marc-Antoine Lucchini (w.e.f July 29, 2020)
Mr. Charles Billard (w.e.f October 01, 2020)

v. Independent Directors

Mr. Aditya Narayan
Mr. Rangaswamy Iyer (till the closure of business of March 30, 2020)
Mrs. Usha Thorat
Mr. Rahul Bhatnagar (w.e.f July 29, 2020)

vi. Transactions during the year

(₹ in Million)

Particulars	December 31, 2021
Ultimate Holding Company	
Dividend paid	-
Expenses recharged	117
Total	117
Holding Company	
Dividend paid	-
Other related Parties	
Sale of Products and Other Operating Income	
Sanofi-Aventis Singapore Pte. Limited	1,925
Others	115
Total	2,040
Purchase of Raw Materials and Stock- in- trade	
Sanofi-Aventis Singapore Pte. Limited	1,925
Others	602
Sanofi Healthcare India Private Limited**	1,671
Total	4,198
Expenses recharged to other companies	
Sanofi-Aventis Groupe S.A.	*
Sanofi Healthcare India Private Limited	1
Others	*
Total	2
Sale of Services	
Sanofi Healthcare India Private Limited	724
Sanofi-Aventis Singapore Pte. Limited	46
Others	7
Total	777
Rent Income	
Sanofi Healthcare India Private Limited	*
Rent Paid	
Sanofi Healthcare India Private Limited	*
Interest income on loans	
Sanofi Healthcare India Private Limited	124
Total	124
Expenses recharged by other companies	
Sanofi Healthcare India Private Limited	34
Sanofi Winthrop Industrie S.A.	9
Sanofi Lanka Limited	26
Sanofi-Aventis Groupe S.A.	7
Others	1
Total	77
Contribution to In-house Trust for Post Employment Benefits - Provident Fund	
Sanofi India Limited Provident Fund #	191
Payment towards Intangibles under development	
Sanofi Healthcare India Private Limited	13
Total	13

Including contribution by employees.

* denotes figure less than a million

(₹ in Million)

Particulars	December 31, 2021
Key Management Personnel Remuneration # #	
Remuneration	
Mr. Rajaram Narayanan	21
Mr. Vaibhav Karandikar	10
Mr. Cherian Mathew	13
Mr. Girish Tekchandani	0
Ms. Radhika Shah	2
Total	46

Share based benefit	
Mr. Rajaram Narayanan	7
Mr. Vaibhav Karandikar	2
Mr. Cherian Mathew	3
Total	11

Excludes Provision for Employee Benefits

Particulars	December 31, 2021
Sitting Fees to Non- Executive Directors	
Mr. Aditya Narayan	*
Ms. Usha Thorat	*
Mr. Rahul Bhatnagar	*
Total	2
Commission to Non - Executive Directors	
Mr. Aditya Narayan	1
Ms. Usha Thorat	*
Mr. Rahul Bhatnagar	*
Total	2

* denotes figure less than a million

Terms and conditions of transactions with related parties

The sales, services and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year ended December 31, 2021, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (December 31, 2020: Nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

vii. Outstanding as at December 31, 2021

Particulars	December 31, 2021
Trade Receivables	
Sanofi-Aventis Singapore Pte. Limited	596
Sanofi Healthcare India Private Limited	332
Others	5
Total	933
Trade Payables	
Sanofi-Aventis Singapore Pte. Limited	475
Sanofi Winthrop Industrie S.A.	11
Francopia S.A.R.L.	534
Sanofi Healthcare India Private Limited	610
Others	32
Total	1,662
Other Financial Liabilities	
Sanofi Healthcare India Private Limited	14
Loan receivable	
Sanofi Healthcare India Private Limited (Refer Note 1 below)	4,450

1) Loans given to Sanofi Healthcare India Private Limited at the rate of interest of 5.5% p.a (9.5 % till April 14 , 2020 and 7.5% till April 15, 2021)

Maximum balance outstanding during the year ₹ 4,450 Million (December 31, 2020 : ₹ 4,450 Million) from Sanofi Healthcare India Private

The said loans have been proposed to be utilized by Sanofi Healthcare India Private Limited for business purpose.

The Loans have been given against corporate guarantee by Sanofi S.A. France. The Maturity date of same is April 15, 2023.

